Defence Therapeutics Inc.

  • ISIN: CA24463V1013
  • Land: Canada

Nachricht vom 05.07.2022 | 08:00

Defence Therapeutics Inc.:  DEFENCE’S ACCUMTM WITH ANTIBODY DRUG CONJUGATES (ADC) IN DEVELOPMENT AGAINST CANCER

DGAP-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous
Defence Therapeutics Inc.:  DEFENCE’S ACCUMTM WITH ANTIBODY DRUG CONJUGATES (ADC) IN DEVELOPMENT AGAINST CANCER
05.07.2022 / 08:00
The issuer is solely responsible for the content of this announcement.

CSE: DTC          FSE: DTC          USOTC: DTCFF            PRESS RELEASE
 

 DEFENCE’S ACCUMTM WITH ANTIBODY DRUG CONJUGATES (ADC) IN DEVELOPMENT AGAINST CANCER

 

Vancouver, BC, Canada, July 5th, 2022 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to provide an update on its ADC programs in development using Defence’s AccumTM, including key in vivo studies with worldwide collaborators.  

 

The world-renowned Curie Institute, one of Defence’s collaborator, is currently performing therapeutic efficacy study of AccumTM-T-DM1 Antibody Drug Conjugate (“ADC”) in patient-derived xenograft (“PDX”) model of breast cancer, including in 3 HER2+ and in 1 triple-negative PDX. It will be immediately followed by a head-to-head toxicology and pharmacokinetic profile comparisons study of T-DM1 versus AccumTM T-DM1 in mice. Results are expected in Q3-Q4 of this year. T-DM1 (Kadcyla®) is currently used to treat women with metastatic HER2-positive breast cancer. This study is to prove that the current treatment may be optimized using Defence’s AccumTM technology to enhance the drug delivery to the tumor cells. Estimated sales of Kadcyla® in 2022 are $3.02 Billion USD.

https://www.fiercepharma.com/special-report/top-10-antibody-drug-conjugate-contenders-2021#:~:text=In%20the%20first%20half%20of,year%2Dover%2Dyear%20improvement.


 

Defence is continuing its collaboration with the HUS Comprehensive Cancer Center, Finland’s largest and most versatile cancer treatment center, which is currently performing advanced in vivo studies, including head-to-head comparisons of T-DM1 vs AccumTM-T-DM1 vs co-treatment with intratumorally injection of AccuTOXTM variants using different PDX models with established and non-established tumors. Linking the AccumTM to an ADC triggers endosomal escape increasing therefore ADCs intracellular accumulation and cytotoxicity potency. AccuTOXTM variants induce cancer cell death through ROS production and endosome rupture. Results of those key studies with HUS are expected in Q4 of this year.


The Institut de Recherche en Cancérologie de Montpellier (IRCM), an internationally recognized institute for its translational research and expertise’s in immunotherapy and radiotherapy, is currently performing in vivo studies using AccumTM with radio-immuno-therapeutic conjugates. Combining the AccumTM technology to the radio-immuno-conjugate is expected to amplify the therapeutic index of the drug while minimizing side effects observed in patients undergoing the therapy. Results of those studies with IRCM are expected to be known in Q3-Q4 of 2022. The Radiopharmaceuticals Market is projected to reach US$ 13.818 billion by 2028 from US$ 7.55 billion in 2021; it is expected to grow at a CAGR of 9.0% during 2021–2028.

https://www.theinsightpartners.com/reports/radiopharmaceuticals-market

 

Defence is also collaborating with WASSC Technologies, a biotech company specialized in protein conjugations, small molecules, and ADCs, to develop a new small molecule for ADC application. Toxicity results of variants are expected for Q3 of 2022 and antibody conjugation shall begin in Q4 of 2022.

 

"Defence’s AccumTM platform has been primarily developed and tested in vitro and in vivo to enhance the intranuclear drug delivery on multiple FDA approved antibody-conjugates or new conjugates under development. We strongly believe that all those key results coming this year related to AccumTM-ADCs will continue to demonstrate the potency of our AccumTM technology and bring Defence to another level”, says Mr. Sebastien Plouffe, the CEO of Defence Therapeutics.


About Defence:

Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

 

For further information:

Sebastien Plouffe, President, CEO and Director

P: (514) 947-2272

Splouffe@defencetherapeutics.com

www.defencetherapeutics.com

 

Cautionary Statement Regarding “Forward-Looking” Information

 

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

 

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.



05.07.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

Landi Renzo: GBC-Interview mit CEO Christiano Musi

„Der Landi Renzo-Konzern ist ein globaler Akteur, der sich auf die Energiewende entlang der gesamten Wertschöpfungskette spezialisiert hat und darauf abzielt, ein weltweiter Referenzpunkt für RNG- und Wasserstoffanwendungen bei Green Mobility und Clean-Tech-Lösungen zu werden. Bis 2025 erwarten wir Umsatzzuwächse von 15% (CAGR) und ein zweistelliges EBITDA-Wachstum von 25% (CAGR), dank ansteigender Umsätze in Segmenten, die im Vergleich zu unserem traditionellen Markt für leichte Nutzfahrzeuge höhere Margen aufweisen."

Events im Fokus

Termine 2022

12./13. Oktober 2022: Fachkonferenz Finanzdienstleistungen/Technologie

News im Fokus

Henkel AG & Co. KGaA: Henkel steigert Umsatz deutlich, treibt strategische Agenda voran und hebt Umsatzprognose für 2022 an

15. August 2022, 07:30

Aktueller Webcast

HomeToGo SE

Webcast Link

16. August 2022

Aktuelle Research-Studie

APONTIS PHARMA AG

Original-Research: Apontis Pharma AG (von Montega AG): Kaufen

16. August 2022